ODP Pharma

Contact abroad: **Sergio Moskovitz, CEO**Email: smoskovitz@m3qt.com
Contact in Israel: **Amnon Engelberg, Director**

Email: amnonengelberg@gmial.com

ODP Ltd. develops a cutting-edge delivery system for use in the oral cavity. It is designed for the sustained release of Medications & Nutraceuticals.

The Challenge:

Currently, there are no effective mechanisms for long-term sustained local delivery to the oral cavity and upper GI tract. There is a need for a controlled release of medications and nutraceuticals that improve oral and systemic health.

Specifically, conditions that currently lack satisfactory solutions include:

- Oral cavity diseases:
 - Halitosis (Bad Breath)
 - Oral Candidiasis (Oral Thrush)
 - Xerostomia (Dry Mouth)
 - Head & neck and mouth cancer
- Autoimmune diseases
- Orthodontic diseases

Current local oral treatments are dissolved by the saliva and swallowed quickly, and do not stay in the oral cavity.

The Solution: ODP

- An innovative new platform for intra-oral delivery of drugs and nutraceuticals
- Extended time-controlled release
- Non-invasive
- Disposable
- Bio-compatible
- Reduced adverse drug reactions compared to current treatments
- Improved patient compliance self-administered & easy to use
- Designed for convenient use and withstands the oral environment

Prototypes & Possible retention/use ways:







Proprietary, confidential Information

Milestones:

- Platform prototypes available
- Anti-Candidiasis drug In vitro stage completed
- Evaluation of additional candidate drugs in progress
- New IP in the preparation stage
- Compliance tests completed

Major Markets

Medications - Oral drug deliveryretaining controlled levels of medication for extended periods.

Nutraceuticals - Oral care - Vitamins, Minerals & Supplements.

Team

Mr. Sergio MoskovitzCo-founder, CEO and Director

Mr. Amnon Engelberg, **LLb**, **MBA** Co-Founder, Director

Prof. Michael Friedman CSO

Joshua Wolfson Co-Founder, CTO